IP Library Granted Patent US 7,794,935
Granted Patent B2
US 7,794,935 · App. 11/442,525 · Granted Sep 14, 2010

Reverse transcriptase compositions for flap-mediated detection of a target nucleic acid sequence

Assignee: Hologic, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,794,935
App. No.
11/442,525
Granted
Sep 14, 2010
Kind
B2
Abstract

The invention relates to compositions for generating a signal indicative of the presence of a target nucleic acid in a sample. The compositions include a reverse transcriptase, a nuclease, an upstream primer and downstream probe.

Claims (47)

1. A composition comprising:

(i) a target nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(ii) a first oligonucleotide that is at least partially complementary to said first region of said target nucleic acid;

(iii) a second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target nucleic acid and, wherein said 5′ region is not complementary to said target nucleic acid;

(iv) a reverse transcriptase; and

(v) a cleavage means.

2. The composition of claim 1 , wherein said cleavage means comprises a 5′ nuclease.

3. The composition of claim 2 , wherein said 5′ nuclease is a FEN-1 nuclease.

4. The composition of claim 3 , wherein said FEN-1 nuclease is a flap specific nuclease.

5. The composition of claim 3 , wherein said FEN-1 nuclease is thermostable.

6. The composition of claim 1 , wherein said reverse transcriptase is thermostable.

7. The composition of claim 1 , wherein the 3′ nucleotide of said second oligonucleotide has a blocking group.

8. The composition of claim 1 , wherein the second oligonucleotide comprises at least one labeled moiety capable of providing a signal.

9. The composition of claim 1 , wherein the second oligonucleotide comprises a pair of interactive signal generating labeled moieties.

10. The composition of claim 9 , wherein said pair of interactive signal generating moieties comprises a quencher moiety and a fluorescent moiety.

11. The composition of claim 10 , wherein at least one member of the pair of interactive signal generating labeled moieties is operatively coupled to the 5′ region of the second oligonucleotide.

12. The composition of claim 8 , wherein the at least one labeled moiety is operatively coupled to the 5′ region of the second oligonucleotide.

13. A kit comprising a composition of claim 1 and packaging materials therefore.

14. The kit of claim 13 , wherein said cleavage means comprises a 5′ nuclease.

15. The kit of claim 14 , wherein said 5′ nuclease is a FEN-1 nuclease.

16. The kit of claim 13 , wherein the 3′ nucleotide of said second oligonucleotide has a blocking group.

17. The kit of claim 13 , wherein the second oligonucleotide comprises at least one labeled moiety capable of providing a signal.

18. The kit of claim 13 , wherein the second oligonucleotide comprises a pair of interactive signal generating labeled moieties.

19. The kit of claim 18 , wherein said pair of interactive signal generating moieties comprises a quencher moiety and a fluorescent moiety.

20. The kit of claim 18 , wherein at least one member of the pair of interactive signal generating labeled moieties is operatively coupled to the 5′ flap of the second oligonucleotide.

21. The kit of claim 17 , wherein the at least one labeled moiety is operatively coupled to the 5′ flap of the second oligonucleotide.

22. A composition comprising:

(i) a target nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(ii) a first oligonucleotide that is at least partially complementary to said first region of said target nucleic acid;

(iii) a second oligonucleotide corresponding to said target nucleic acid, said second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target nucleic acid and wherein said 5′ region is at least partially complementary to a region that may be upstream of, downstream of, or comprise said first region of said target nucleic acid;

(iv) a reverse transcriptase; and

(v) a cleavage means.

23. A kit comprising the composition of claim 22 and packaging materials therefore.

24. A composition comprising:

(i) a template nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(ii) a first oligonucleotide that is at least partially complementary to said first region of said target template nucleic acid;

(iii) a second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target template nucleic acid and wherein said 5′ region is not complementary to said target template nucleic acid;

(iv) a reverse transcriptase; and

(v) a cleavage means.

25. A kit comprising the composition of claim 24 and packaging materials therefore.

26. A composition comprising:

(i) a template nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(ii) a first oligonucleotide that is at least partially complementary to said first region of said template nucleic acid;

(iii) a second oligonucleotide corresponding to said template nucleic acid, said second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said template nucleic acid and wherein said 5′ region is at least partially complementary to a region that may be upstream of, downstream of, or comprise said first region of said template nucleic acid;

(iv) a reverse transcriptase; and

(v) a cleavage means.

27. A kit comprising the composition of claim 26 and packaging materials therefore.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
EIGHTH SUPPLEMENT TO PATENT SECURITY AGREEMENT Recorded Mar 26, 2009
From: CYTYC CORPORATION; HOLOGIC, INC.
To: GOLDMAN SACHS CREDIT PARTNERSL.P.
Reel/Frame 022456/0947 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2008
From: STRATAGENE CALIFORNIA
To: HOLOGIC INC.
Reel/Frame 021976/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2006
From: SORGE, JOSEPH A.
To: STRATAGENE CALIFORNIA
Reel/Frame 018446/0637 →
Continuity (7)
Division 1098194200 · Nov 15, 2004
Division 0971760200 · Nov 21, 2000
Division 1144252500
Continuation In Part 0972857400 · Nov 30, 2000
Continuation In Part 0965088800 · Aug 30, 2000
Continuation In Part 0943069200 · Oct 29, 1999
Related Publication 20070099205A1 · May 3, 2007